|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.42 USD | +2.32% |
|
+2.02% | +11.83% |
| 08-05 | Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL | MT |
| 08-05 | Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Other Pharmaceuticals | +2.44% | +2.02% | +11.83% | +21.41% | +6.18% | 54.68B |
-
|
-
|
-
|
Select your edition
All financial news and data tailored to specific country editions
